Answers are grounded in this paper and cite their sources.
A 15-year-old girl presented with diabetes mellitus without ketoacidosis, initially treated as type 1 diabetes (T1DM). Despite a family history of diabetes, the patient showed reduced insulin requirements (0.3 U/kg/day) and tested negative for autoantibodies associated with T1DM. Following ISPAD guidelines, genetic testing was performed, revealing a heterozygous mutation in the HNF4α gene, associated with MODY 1 (Maturity-Onset Diabetes of the Young). The patient maintained good glycemic control with insulin therapy, but the case raises questions about the timing and approach to transitioning to sulfonylureas, the first-line treatment for MODY 1, which could potentially improve glycemic control and the quality of life.
No takes yet. Share an insight, caveat, or question.
Gulisano et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: